



**Date:** September 22, 2021

**To:** Office of the Attorney General of Vermont

**Re:** Vermont New Drug Notice

**Via Email:** AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A. § 4637(b), Takeda Pharmaceuticals America is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on September 20<sup>th</sup>, 2021.

The new product being launched is: EXKIVITY™, NDC: 63020-0040-12.

Sincerely,

Michelle Lucas

Government Pricing and Reporting Lead

***Takeda Pharmaceuticals America, Inc.***

email: michelle.lucas@takeda.com